abrdn plc Has $27.07 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

abrdn plc trimmed its position in DexCom, Inc. (NASDAQ:DXCM) by 9.6% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 347,551 shares of the medical device company’s stock after selling 37,095 shares during the period. abrdn plc’s holdings in DexCom were worth $27,071,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of DXCM. Jennison Associates LLC lifted its stake in shares of DexCom by 1,683.2% in the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after buying an additional 6,544,102 shares during the last quarter. Westfield Capital Management Co. LP lifted its stake in shares of DexCom by 44.6% in the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after buying an additional 876,739 shares during the last quarter. Two Sigma Advisers LP raised its stake in DexCom by 182.7% during the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock valued at $76,659,000 after purchasing an additional 739,000 shares during the last quarter. Intech Investment Management LLC raised its stake in DexCom by 2,083.0% during the 3rd quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company’s stock valued at $25,967,000 after purchasing an additional 369,587 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in DexCom by 53.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 989,740 shares of the medical device company’s stock valued at $66,352,000 after purchasing an additional 345,114 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the sale, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 42,342 shares of company stock worth $3,628,069. Company insiders own 0.30% of the company’s stock.

DexCom Stock Performance

DexCom stock opened at $88.78 on Thursday. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a market cap of $34.68 billion, a PE ratio of 53.16, a PEG ratio of 2.23 and a beta of 1.14. The company’s 50-day moving average is $81.14 and its two-hundred day moving average is $75.60.

Wall Street Analysts Forecast Growth

DXCM has been the subject of several research analyst reports. JPMorgan Chase & Co. upped their target price on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Oppenheimer cut their target price on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Raymond James cut their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. Wells Fargo & Company upped their target price on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Finally, Leerink Partners cut their target price on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, DexCom has an average rating of “Moderate Buy” and an average target price of $98.41.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.